ENTRY       D00617                      Drug
NAME        Nicardipine hydrochloride (JP18/USAN);
            Cardene (TN)
PRODUCT     CARDENE IV (Baxter Healthcare Corporation)
            CARDENE IV (Baxter Healthcare Corporation)
            CARDENE IV (Baxter Healthcare Corporation)
            NICARDIPINE HYDROCHLORIDE (HF Acquisition Co LLC)
            NICARDIPINE HYDROCHLORIDE (HF Acquisition Co LLC)
            NICARDIPINE HYDROCHLORIDE (Hikma Pharmaceuticals USA)
            NICARDIPINE HYDROCHLORIDE (Hikma Pharmaceuticals USA)
            NICARDIPINE HYDROCHLORIDE (West-Ward Pharmaceuticals Corp)
  GENERIC   NICARDIPINE HYDROCHLORIDE (ANI Pharmaceuticals)
            NICARDIPINE HYDROCHLORIDE (American Regent)
            NICARDIPINE HYDROCHLORIDE (AuroMedics Pharma LLC)
            NICARDIPINE HYDROCHLORIDE (AuroMedics Pharma LLC)
            NICARDIPINE HYDROCHLORIDE (Burel Pharmaceuticals)
            NICARDIPINE HYDROCHLORIDE (Civica)
            NICARDIPINE HYDROCHLORIDE (Epic Pharma)
            NICARDIPINE HYDROCHLORIDE (Glenmark Pharmaceuticals)
            NICARDIPINE HYDROCHLORIDE (PuraCap Laboratories LLC dba Blu Pharmaceuticals)
            NICARDIPINE HYDROCHLORIDE (SQUARE PHARMACEUTICALS LIMITED)
            NICARDIPINE HYDROCHLORIDE (Wockhardt USA LLC.)
FORMULA     C26H29N3O6. HCl
EXACT_MASS  515.1823
MOL_WEIGHT  515.9859
CLASS       Cardiovascular agent
             DG01575  Calcium channel blocker
              DG01496  Calcium channel L type blocker
             DG03231  Antihypertensive
              DG01928  Dihydropyridine calcium channel blocker
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2149
            ATC code: C08CA04
            Chemical structure group: DG00323
            Product (DG00323): D00617<JP/US>
EFFICACY    Antihypertensive, Vasodilator, Calcium channel blocker
  DISEASE   Hypertension [DS:H01633]
COMMENT     Dihydropyridine derivative
TARGET      CACNA1-L [HSA:775 776 778 779] [KO:K04850 K04851 K04853 K04857]
  PATHWAY   hsa04020(775+776+778+779)  Calcium signaling pathway
            hsa04260(775+776+778+779)  Cardiac muscle contraction
            hsa04261(775+776+778+779)  Adrenergic signaling in cardiomyocytes
            hsa04270(775+776+778+779)  Vascular smooth muscle contraction
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07036  Calcium channel blocking drugs
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C08 CALCIUM CHANNEL BLOCKERS
               C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
                C08CA Dihydropyridine derivatives
                 C08CA04 Nicardipine
                  D00617  Nicardipine hydrochloride (JP18/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Cardiovascular Agents
              Calcium Channel Blocking Agents, Dihydropyridines
               Nicardipine
                D00617  Nicardipine hydrochloride (JP18/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               214  Antihypertensives
                2149  Others
                 D00617  Nicardipine hydrochloride (JP18/USAN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01575  Calcium channel blocker
               DG01496  Calcium channel L type blocker
                DG00323  Nicardipine
                 D00617  Nicardipine hydrochloride
              DG03231  Antihypertensive
               DG01928  Dihydropyridine calcium channel blocker
                DG00323  Nicardipine
                 D00617  Nicardipine hydrochloride
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00323  Nicardipine
                 D00617  Nicardipine hydrochloride
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG01928  Dihydropyridine calcium channel blocker
               D00617  Nicardipine hydrochloride
              DG03231  Antihypertensive
               D00617  Nicardipine hydrochloride
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Voltage-gated ion channels
               Calcium channels
                CACNA1-L
                 D00617  Nicardipine hydrochloride (JP18/USAN) &lt;JP/US&gt;
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00617  Nicardipine hydrochloride
              D00617  Nicardipine hydrochloride injection
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00617
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01575  Calcium channel blocker
               DG01496  Calcium channel L type blocker
                DG00323  Nicardipine
              DG03231  Antihypertensive
               DG01928  Dihydropyridine calcium channel blocker
                DG00323  Nicardipine
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00323  Nicardipine
DBLINKS     CAS: 54527-84-3
            PubChem: 7847683
            ChEBI: 7551
            LigandBox: D00617
            NIKKAJI: J245.477G
ATOM        36
            1   C1y C    19.9164  -15.4819
            2   C8y C    19.9164  -16.8638
            3   C2y C    21.1058  -14.7939
            4   C2y C    18.7210  -14.7939
            5   C8x C    21.1175  -17.5519
            6   C8x C    18.7327  -17.5519
            7   C2y C    21.1058  -13.4118
            8   C7a C    22.3071  -15.4819
            9   C2y C    18.7210  -13.4118
            10  C7a C    17.5256  -15.4877
            11  C8y C    21.1234  -18.9280
            12  C8x C    18.7327  -18.9339
            13  N1x N    19.9164  -12.7238
            14  C1a C    22.3071  -12.7238
            15  O7a O    23.5024  -14.7939
            16  O6a O    22.3071  -16.8638
            17  C1a C    17.5256  -12.7238
            18  O7a O    16.3244  -14.7939
            19  O6a O    17.5256  -16.8638
            20  C8x C    19.9280  -19.6220
            21  N2b N    22.3245  -19.6220 #+
            22  C1b C    24.6976  -15.4819
            23  C1a C    15.1290  -15.4877
            24  O3a O    23.8231  -18.6598
            25  O3a O    22.3536  -21.3130 #-
            26  C1b C    25.8989  -14.7880
            27  N1c N    27.0884  -15.4819
            28  C1b C    28.2837  -14.7880
            29  C1a C    27.0943  -16.8638
            30  C8y C    29.4791  -15.4760
            31  C8x C    29.4791  -16.8581
            32  C8x C    30.6804  -14.7880
            33  C8x C    30.6804  -17.5461
            34  C8x C    31.8757  -15.4760
            35  C8x C    31.8757  -16.8581
            36  X   Cl   35.0069  -16.2400
BOND        37
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 2
            6     3   7 2
            7     3   8 1
            8     4   9 2
            9     4  10 1
            10    5  11 2
            11    6  12 1
            12    7  13 1
            13    7  14 1
            14    8  15 1
            15    8  16 2
            16    9  17 1
            17   10  18 1
            18   10  19 2
            19   11  20 1
            20   11  21 1
            21   15  22 1
            22   18  23 1
            23   21  24 2
            24   21  25 1
            25   22  26 1
            26   26  27 1
            27   27  28 1
            28   27  29 1
            29   28  30 1
            30   30  31 2
            31   30  32 1
            32   31  33 1
            33   32  34 2
            34   33  35 2
            35    9  13 1
            36   12  20 2
            37   34  35 1
///
